Skip to main content


Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting
Quick Connect

Mirogabalin Besylate

Mirogabalin Besylate API

Mirogabalin Besylate-API

CAS Number: 1138245-21-2

Therapeutic Category
Pain Management
API Technology
Synthetic
Dose Form
Oral Solid/Tablets
Dr Reddy's Development Status
Under-Development
Innovator Brand (USA)
Tarlige
Plant
EMQA
No Document Available
Off
Region/Country
China

Mechanism of Action

Miragabalin is a novel, orally-administered small molecule that acts as a selective modulator of alpha2-delta subunit of voltage-gated calcium channels in the central nervous system.

The alpha2-delta subunit is expressed in dorsal root ganglia and is involved in regulation of neurotransmitter release. By binding to the alpha2-delta subunit, Miragabalin reduces the release of excitatory neurotransmitters such as glutamate and substance P, leading to a reduction in neuronal hyperexcitability.

Miragabalin's mechanism of action results in a reduction of chronic pain, particularly neuropathic pain and pain associated with fibromyalgia. It is believed to work by reducing the activity of nerve cells that transmit pain signals, which can result in a decrease in pain perception.

Indication

Miragabalin (brand name Neuramend) is indicated for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN) and fibromyalgia.

Diabetic peripheral neuropathy is a type of nerve damage that can occur in people with diabetes and is characterized by pain, numbness, tingling, and weakness in the hands and feet. Fibromyalgia is a chronic pain disorder that is characterized by widespread musculoskeletal pain, fatigue, and tenderness in localized areas.

Miragabalin is used as an adjunctive treatment, which means it is used in combination with other pain medications to provide additional pain relief. It is taken orally and is available in tablet form.

Dr. Reddy's Expertise

Headquartered in Hyderabad, India, Dr. Reddy's Laboratories is one of the leading Active Pharmaceutical Ingredients (API) manufacturers and suppliers globally for Mirogabalin Besylate API. Dr. Reddy's API business is a preferred partner to pharma companies across the US, Europe, Brazil, Latin America, Japan, China, Korea, Middle East and other emerging markets.

Dr. Reddy's API business thrives on the deep technical strengths established over the last 30+ years in the development and manufacture of complex APIs such as steroids, peptides, complex long chain molecules and highly potent APIs (HPAPIs / oncology drugs). This expertise is complemented by our prowess in intellectual property and regulatory affairs which helps us consistently meet and exceed regulatory standards. Dr. Reddy's Mirogabalin Besylate API is the outcome of the extensive expertise in R&D, IP, and Regulatory.

A key component in helping our customers be first to market is a responsive supply chain. We achieve this by making sure that all our facilities are operating efficiently and to the latest standards of quality, safety, and productivity. A strong interconnect between business and factories allows for a quick reaction to dynamic market changes, so that we can avert shortages and meet sudden surges in demand.

Contact Us

Please fill in the following form for API Requirement & we'll get back to you shortly

We are here to help, if you have any country specific requirements.

Disclaimer

No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.